Overview

A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients

Status:
Terminated
Trial end date:
2017-04-02
Target enrollment:
Participant gender:
Summary
The purpose of this study, a follow up to study FG506-CL-0403, is to see how safe and effective Modigraf® is (Part A) and to see how safe and effective it is to change your child's medication from Modigraf® to Prograf® (Part B).
Phase:
Phase 4
Details
Lead Sponsor:
Astellas Pharma Europe Ltd.
Treatments:
Tacrolimus